BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12167578)

  • 1. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients.
    Swetter SM; Carroll LA; Johnson DL; Segall GM
    Ann Surg Oncol; 2002 Aug; 9(7):646-53. PubMed ID: 12167578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 9:45-10:00. Positron Emission Tomography (PET) is Superior to Computerized Tomography (CT) for Metastatic Staging in Melanoma Patients.
    Swetter S; Carroll L; Johnson D; Segall G
    Clin Positron Imaging; 2000 Jul; 3(4):154. PubMed ID: 11150757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
    Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
    J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
    Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
    Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of positron emission tomography for the detection of melanoma metastases.
    Holder WD; White RL; Zuger JH; Easton EJ; Greene FL
    Ann Surg; 1998 May; 227(5):764-9; discussion 769-71. PubMed ID: 9605668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
    Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
    Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study.
    Riquelme-Mc Loughlin C; Podlipnik S; Bosch-Amate X; Riera-Monroig J; Barreiro A; Espinosa N; Moreno-Ramírez D; Giavedoni P; Vilana R; Sánchez M; Vidal-Sicart S; Carrera C; Malvehy J; Puig S
    J Am Acad Dermatol; 2019 Dec; 81(6):1330-1338. PubMed ID: 31163236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
    Clark PB; Soo V; Kraas J; Shen P; Levine EA
    Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
    Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
    J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
    Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
    Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
    Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
    J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.
    Rinne D; Baum RP; Hör G; Kaufmann R
    Cancer; 1998 May; 82(9):1664-71. PubMed ID: 9576286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
    Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
    J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma.
    Klingenstein A; Haug AR; Nentwich MM; Tiling R; Schaller UC
    Melanoma Res; 2010 Dec; 20(6):511-6. PubMed ID: 20890225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma.
    Niederkohr RD; Rosenberg J; Shabo G; Quon A
    Nucl Med Commun; 2007 Sep; 28(9):688-95. PubMed ID: 17667747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma.
    Veit-Haibach P; Vogt FM; Jablonka R; Kuehl H; Bockisch A; Beyer T; Dahmen G; Rosenbaum S; Antoch G
    Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):910-8. PubMed ID: 19156409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline staging in cutaneous malignant melanoma.
    Hafner J; Schmid MH; Kempf W; Burg G; Künzi W; Meuli-Simmen C; Neff P; Meyer V; Mihic D; Garzoli E; Jungius KP; Seifert B; Dummer R; Steinert H
    Br J Dermatol; 2004 Apr; 150(4):677-86. PubMed ID: 15099363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.